17,261 trials
Rhinoconjunctivitis · Rhinitis · Conjunctivitis
Primary: The Proportion of Participants Reporting Treatment-emergent Adverse Events (AEs) — 0.446; 0.515; 0.615 Proportion of Participants — p=0.486
Generalized Anxiety Disorder (GAD) · Anxiety, Separation · Phobia, Social
Primary: Change From Baseline in Systolic Blood Pressure at Up to 12 Weeks — -1.7; -2.3 mmHg
Colorectal Cancer · Carcinoma, Neuroendocrine · Neoplasm Metastasis
Primary: Hepatic Progression-free Survival According to Response Evaluation Criterian in Solid Tumors (RECIST) — 3.0; 17.9; 2.9; 3.4 Months
Multiple Myeloma
Primary: Phase I - Maximum Tolerated Dose (MTD) Level — 127.8; 30 mg/m^2
Diabetes Mellitus, Type 2
Primary: Area Under the Plasma Concentration Versus Time Curve (AUC) From Time Zero to Infinity (0-inf) of Albiglutide in the Bioequivalence (BE) Phase — 496190.200; 464985.355…
Stress Disorders, Post-Traumatic · Depression
Primary: Post-traumatic Stress Disorder Symptoms — 17.46; 19.41; 13.72; 18.32 units on a scale
Influenza · Avian Influenza · Severe Influenza
Primary: Proportion of All Participants Negative for Viral RNA on Day 5 — 115; 105 participants — p=0.42
Non Small Cell Lung Cancer
Primary: Percentage of Participants With Complete Response (CR) or Partial Response (PR) [Overall Response Rate (ORR)] — 41.2 percentage of participants
Recurrent Non-small Cell Lung Cancer · Stage IIIB Non-small Cell Lung Cancer · Stage IV Non-small Cell Lung Cancer
Primary: Response Per RECIST Criteria — 0 participants
Accelerated Phase Chronic Myelogenous Leukemia · Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative · Blastic Phase Chronic Myelogenous Leukemia
Primary: Response Rate Including Complete Response, Partial Response, and Hematological Improvement Assessed by Blood Cell Counts, Number of Blasts in Bone Marrow, and Clinical…
Leukemia
Primary: Recommended Phase 2 Dose (RP2D) of BMS-833923 Plus Dasatinib in Chronic Myeloid Leukemia-Chronic Phase — 50 mg
Acne Vulgaris
Primary: Photoactive Porphyrins Level — 33.0; 24.8; 19.7 Fluorescence intensity unit
Fabry Disease
Primary: Number of Serious Adverse Event (SAE) — 0 events
Phobic Disorders · Anxiety · Social Phobia
Primary: Clinical Global Improvement (CGI-S) Scale — 4.167; 3.833 units on a scale
Prostate Cancer
Primary: PSA Response Rate — 15.4 percentage of participants